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Background
Aurora Kinase A (AurkA), one of the key regulators of
M phase progression, is over-expressed in melanoma
and has been observed to limit tumor growth [1,2]. The
potential use of this molecule as target for biological
therapy in melanoma has been examined.
Materials and methods
A375mel (BRAFV600E) melanoma cell line was used in
this study. The cell line was exposed to B-RAF inhibitor
(GSK2118436), MEK inhibitor (GSK1120212) and
AurkA inhibitor (MLN8054) as single agents or in var-
ious combinations (B-RAF plus AurkA inhibitor, MEK
plus AurkA inhibitor) or in triple combination (B-RAF
plus MEK plus AurkA inhibitor).
The effects on the cell growth of drugs, used as single
agents and as different combinations, were examined by
the xCELLigence technology. Total protein extracts
were examined for p53 and c-myc protein expression by
Western Blot analysis. The drug’s efficacy was also
tested by using a 3D-human melanoma skin reconstruc-
tion model.
Results
A375 (BRAFV600E) melanoma cells treatment with
AurkA inhibitors in combination with B-RAF and/or
MEK inhibitors alone and/or with both B-RAF/MEK
inhibitors, increased the anti-tumor efficacy of the drugs
than given as single agents.
The AurkA inhibitors enhancing anti-melanoma
effect on B-RAF and MEK inhibitors was furthermore
confirmed in a 3D-human melanoma model, where it
was restricted to a melanoma cell sub-population loca-
lized at epithelial/dermal junction site. However, S-100
and Ki-67 positively stained spindle-shaped cells were
detected in the dermal stratum, suggesting the pre-
sence of alive and proliferating melanoma cells.
Conclusions
These findings provide new prospects for melanoma
research. For the first time, based on these results, it
was observed that the triple combination treatment was
more efficacious as anti-melanoma therapy. Interesting,
the treatment was efficacious only on polygonal-shaped
melanoma cells present at the epidermal/dermal junc-
tion site as small nests, while spindle-shaped melanoma
cells present in the dermal stratum remained alive and
proliferating. This finding suggested that these cells may
account of the drug resistance and so be responsible of
disease recurrence later on. Molecular characterization
of these dermal cells may be critical for the development
of novel therapeutic strategies.
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